Eesti - eesti - Ravimiamet

menarini international operations luxembourg s.a. - tamsulosiin - toimeainet modifitseeritult vabastav kõvakapsel - 0,4mg 200tk; 0,4mg 30tk; 0,4mg 100tk; 0,4mg 56tk; 0,4mg 20tk; 0,4mg 90tk; 0,4mg 14tk; 0,4mg 28tk

Eesti - eesti - Ravimiamet

lex ano uab - tamsulosiin - toimeainet modifitseeritult vabastav kõvakapsel - 0,4mg 30tk

Eesti - eesti - Ravimiamet

dopharma research b.v. - tülosiin - graanulid joogivees manustamiseks - 1000mg 1g 5000g 1tk; 1000mg 1g 800g 1tk; 1000mg 1g 550g 1tk; 1000mg 1g 100g 1tk; 1000mg 1g 1000g 1tk

Eesti - eesti - Ravimiamet

vetoquinol s.a. - tülosiin - süstelahus - 200mg 1ml 100ml 1tk; 200mg 1ml 50ml 1tk; 200mg 1ml 250ml 1tk

Eesti - eesti - Ravimiamet

huvepharma - tülosiin - suukaudse lahuse pulber - 500mg 1g 1000g 1tk

Eesti - eesti - Ravimiamet

ceva sante animale - tülosiin - süstelahus - 200mg 1ml 50ml 1tk; 200mg 1ml 100ml 1tk; 200mg 1ml 250ml 1tk

Eesti - eesti - Ravimiamet

interchemie werken de adelaar eesti aktsiaselts - tülosiin - süstelahus - 200mg 1ml 100ml 1tk

Eesti - eesti - Ravimiamet

huvepharma - tülosiin - süstelahus - 200mg 1ml 50ml 1tk

Eesti - eesti - Ravimiamet

norbrook laboratories limited - tülosiin - süstesuspensioon - 150mg 1ml 100ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.